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Abstract
Background: Hyperphosphatemia is one of the common complications in patients undergoing hemodialysis.
Although calcium carbonate (CaC) is often used to control serum inorganic phosphorus level in dialysis patients,
co-administration of gastric acid reducers (ARs) may interfere with the phosphate binding effect of CaC. We
performed a retrospective medical chart review to study whether ARs attenuate the hypophosphatemic effect of
CaC in patients undergoing hemodialysis.
Methods: One hundred and eight chronic hemodialysis patients receiving either CaC alone or CaC concomitant
with one of the ARs (proton pump inhibitors and histamine H2-receptor antagonists) were retrieved from the
medical charts in Juntendo University Nerima Hospital. The patients were subdivided according to the interval
between hemodialysis sessions (interdialysis interval of 48 or 72 h). A multivariate analysis was performed to identify
clinical covariates associated with the variability of serum inorganic phosphorus levels. The study protocol was
approved by the Institutional Review Board before the study was begun.
Results: Among patients on hemodialysis with a 72-h interdialysis interval, the magnitude of increase in serum
inorganic phosphorus concentration in patients receiving CaC and AR was significantly greater than in those
receiving CaC alone. While a similar trend was observed among patients with a 48-h interdialysis interval, the
difference did not reach a significant level. A multivariate regression analysis revealed that concomitant
administration of ARs with CaC and a longer interdialysis interval (72 h) were significantly and independently
associated with the magnitude of increase in serum phosphorus concentration between dialysis sessions. No
significant differences in albumin-corrected serum calcium concentrations and incidence of pathological fractures
were observed between patients receiving CaC alone and those receiving CaC with ARs.
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Conclusions: Concomitant use of ARs with CaC may attenuate the hypophosphatemic effect of CaC in patients
undergoing chronic hemodialysis. When hemodialysis patients require prescription of ARs for the prevention of
upper gastrointestinal mucosal diseases (such as peptic ulcer), it may be prudent to choose a phosphate binder
other than CaC.
Keywords: Drug interactions, Proton pump inhibitors, Histamine H2 receptor antagonists, Calcium carbonate,
hemodialysis, Retrospective studies
Background
Hyperphosphatemia is one of the common complications
in patients with end-stage renal disease (ESRD) undergo-
ing hemodialysis. Impaired renal phosphorus excretion
causes hyperphosphatemia and may lead secondarily to
hypocalcemia according to the physicochemical inverse
equilibrium between phosphorus and calcium ions. Hypo-
calcemia triggers secondary hyperparathyroidism that may
ultimately result in renal osteodystrophy and pathological
fracture as well as ectopic calcification [1]. Collectively,
hyperphosphatemia alone or in combination with hypercal-
cemia has been associated with increased cardiovascular and
musculoskeletal morbidity and mortality in hemodialysis
patients [2, 3]. In this context, management of serum
inorganic phosphorus level is clinically important. Restric-
tion of dietary phosphate intake, oral administration of
phosphate binder, and more intensive hemodialysis are
commonly recommended for the prevention and treatment
of hyperphosphatemia in patients undergoing chronic
hemodialysis. As for the choice of phosphate binder,
calcium carbonate (CaC) may be preferred to lanthanum
carbonate or sevelamer hydrochloride when safety profile
or lower cost is of primary concern.
Because ESRD patients commonly take low-dose as-
pirin for the prevention of atherosclerotic cardiovascular
diseases [4–6], they often develop acid-related upper
gastrointestinal diseases (including peptic ulcer and reflux
esophagitis) [7] and frequently take one of the proton
pump inhibitors (PPIs) or histamine H2 receptor antago-
nists (H2RAs). There is a concern that administration of
these gastric acid reducers (ARs) may interfere with the
phosphate binding effect of CaC [8–11]. The dissolution
rate of tablet formulation of precipitated CaC is strongly
pH dependent. In vitro dissolution tests demonstrated a
mean dissolution rate of 99.7% within 10 min at pH 1.2,
but only 10.9% by 360 min at pH 6.8 [12]. As a result,
concomitant administration of ARs with CaC may at-
tenuate the dissolution of CaC formulation, consequently
releasing less free calcium ions to bind phosphate ions
derived from food [12–14]. Previous clinical studies,
however, have reported controversial results regarding
the interaction between ARs and CaC [15, 16].
We hypothesize that different study designs adopted
in previous studies may account for the contradictory
results obtained for the interaction between ARs and CaC.
There are large variations in pre- and post-hemodialysis
serum inorganic phosphorus concentrations and in the
interval between hemodialysis sessions among patients. As
a result, the interaction would be most effectively studied
by comparing serum inorganic phosphorus concentrations
using paired data from the same patients and by consider-
ing the length of hemodialysis intervals (usually either 48
or 72 h). Theoretically, the effect of drug interaction be-
tween ARs and CaC is greater as the interval between
hemodialysis sessions (interdialysis interval) increases. In
this study, we performed a retrospective medical chart
review to analyze the interaction between ARs and CaC
based on the change in serum inorganic phosphorus
concentration from after dialysis to just before dialysis
session in the same patients, adjusting for the interdialysis
interval.
Methods
Study design and data retrieval
The present study was performed by retrospectively
reviewing patients’ data extracted from electronic med-
ical records archived at Juntendo University Nerima
Hospital, Japan. First, ESRD patients undergoing main-
tenance hemodialysis from January 2006 to December
2014 were retrieved from the electronic medical re-
cords. Patients who received CaC for the treatment of
hyperphosphatemia were extracted, and those taking ei-
ther sevelamer or lanthanum with CaC were excluded.
From the medical records, those that had blood chemistry
data obtained immediately after and before hemodialysis
within 1 month under stable and comparable dialysis con-
ditions in the same patients were considered eligible data
sets. Patients with variable hemodialysis conditions during
the study period were excluded. The paired data of each
patient were searched chronologically over the study
period, and the earliest pair of post- and pre-hemodialysis
(post-HD and pre-HD) data obtained within 1 month was
collected. The patients were stratified according to the
interdialysis interval (48 or 72 h). It should be noted that
the pair of post-HD and pre-HD data set were not neces-
sarily collected at an interval of 48 or 72 h, because serum
data obtained after a hemodialysis session was paired with
those obtained before a session sometime within 1 month.
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One data set pair was obtained from one patient. CaC was
prescribed as a tablet formulation (500 mg) of precipitated
CaC (Sanwa Kagaku Kenkyusho Co., Ltd.). While pharma-
cists instructed patients to ingest the CaC tablet during
meal, they could not confirm if the patients adhered to the
instruction. Dialysate contained sodium (140 mEq/L), po-
tassium (2.0 mEq/L), calcium (3.0 mEq/L), magnesium
(1.0 mEq/L), chloride (111 mEq/L), bicarbonate (35 mEq/
L) and glucose (1.5 g/L). Cellulose triacetate dialyzers and
polysulfone dialyzers were used in approximately 70% and
30% of the patients, respectively. The protocol of the
present study was written according to the ethics guide-
lines for clinical studies and was reviewed and approved
by the Institutional Review Board at Juntendo University
Nerima Hospital (reference number: 27-04).
Assessment of interaction between AR and CaC
Patients were divided into two groups: those taking ARs
with CaC (the AR + CaC group) and those taking CaC
only (the CaC group). Glomerular filtration rate was
calculated by the Modification of Diet in Renal Disease
(MDRD) equation for Japanese [17] using serum cre-
atinine levels obtained before hemodialysis session. We
assessed whether the hypophosphatemic effect of CaC
is affected by co-administration with ARs by comparing
the difference between post-HD and pre-HD serum inor-
ganic phosphate levels in the same patients. The statistical
analyses were performed for the data combining those ob-
tained from patients irrespective of dialysis intervals (i.e.,
48 h or 72 h) together (the main analysis) and for those
stratified into 48-h and 72-h dialysis intervals separately
(the subgroup analysis). For analyzing whether there is a
difference in the magnitude of anti-hypophosphatemic ef-
fect between ARs, we compared the changes in serum
phosphate concentrations during dialysis intervals ob-
tained from patients given different ARs. We also exam-
ined whether there is an imbalance in the dialysis intervals
for each AR data. Furthermore, we also examined whether
coadministration of ARs with CaC influences albumin-
corrected serum calcium level or the incidence of fracture
events in the AR + CaC and CaC groups. Fracture was di-
agnosed by plain X-ray findings, together with computed
tomography findings if necessarily.
Statistical analysis
Student’s t-test was used to compare the mean values of
continuous variables (such as age) between the AR +CaC
and CaC groups. Chi-square test or Fisher’s exact test was
used for comparisons of categorical variables (such as sex).
One-way ANOVA was employed for multiple compari-
sons of changes in serum phosphate levels during the
interdialysis period irrespective of the dialysis intervals
(i.e., 48 and 72 h) in patients who received different
ARs with CaC. For the subgroup analysis assessing the
effects for 48-h and 72-h dialysis intervals separately,
we employed a post-hoc Bonferroni’s correction (k = 2)
for suppressing overall the type I error <0.05. Compari-
sons of the magnitude of the drug interaction between
different ARs and CaC were made using ANOVA after
heterogeneity in the distribution of dialysis intervals
across different ARs was examined by the Fischer’s exact
test. A multiple regression analysis was performed to
examine whether co-administration of ARs and other clin-
ical covariates (sex, age, dry weight, daily dose of CaC,
interdialysis interval, and residual renal function assessed
by glomerular filtration rate) are associated with the
variability of serum inorganic phosphorus levels. We
used JMP Pro 11 (SAS Institute Inc., North Carolina,
USA) for all statistical analyses, and chose 0.05 as the
critical value of the type I error throughout the study.
Data are expressed as mean ± standard deviation, median




Among the 526 hemodialysis patients taking CaC as a
phosphate binder at Juntendo University Nerima Hospital
during the study period, 108 patients were eligible to
enter the present study according to the inclusion and
exclusion criteria (Fig. 1). Among them, 23 patients
(aged 66 ± 12 years, 14 males) were assigned to the CaC
group and 85 (aged 70 ± 12 years, 55 males) to the AR +
CaC group. Thirty-six patients (9 and 27 in the CaC and
the AR + CaC group, respectively) and 72 patients (14 and
58 in the CaC and the AR + CaC group, respectively) had
interdialysis intervals of 48 and 72 h, respectively. Table 1
shows the patients’ demographic data, laboratory tests,
underlying diseases and concomitant medications.
While the mean daily dose of CaC in the AR + CaC
group (2.5 ± 1.3 g/day) tended to be higher than that in
the CaC group (1.9 ± 1.1 g/day), the difference did not
reach statistical significance (p = 0.062). When the CaC
doses were compared between the CaC and AR + CaC
groups for interdialysis intervals of 48 and 72 h separ-
ately, essentially similar results were obtained (data are
not shown). No significant difference in the percentage of
patients receiving vitamin D3 analogues was observed be-
tween the CaC and AR + CaC groups (p = 0.466). No sig-
nificant differences were observed between two groups in
biochemical data (including pre-HD creatinine and blood
urea nitrogen) possibly related to hemodialysis conditions.
Serum inorganic phosphorus levels
Figure 2 shows serum inorganic phosphorus levels ob-
tained from patients in the CaC and AR + CaC groups
before and after hemodialysis session (post-HD and
pre-HD, respectively). The data obtained from the same
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patients are connected by lines. The mean change in serum
inorganic phosphate obtained from the AR +CaC group
(2.2 ± 1.0 mg/dL) was significantly (p = 0.001) greater than
that obtained from the CaC group (1.5 ± 0.8 mg/dL). Next,
the patients were stratified into 48-h and 72-h interdialysis
intervals, and the data of the AR +CaC and CaC groups
were compared for each interval. For the 72-h interdialysis
interval, the mean change in serum inorganic phosphorus
concentration was significantly greater in the AR +CaC
group than in the CaC group (2.3 ± 1.0 vs. 1.6 ± 0.8 mg/dL,
p = 0.021, Fig. 3b). For the 48-h interdialysis interval, while
the mean change in serum inorganic phosphorus concen-
tration tended to the higher in the AR +CaC group than in
the CaC group, the difference did not reach a statistical sig-
nificance (1.9 ± 0.8 vs. 1.3 ± 0.8 mg/dL, p = 0.118, Fig. 3a).
Multiple regression analysis identified concomitant use of
ARs with CaC and interdialysis interval of 72 h as signifi-
cant (p = 0.002 and 0.043, respectively) independent vari-
ables associated positively with the variability in changes of
serum inorganic phosphorus level during the interdialysis
interval, while the other covariates (sex, age, dry weight,
daily dose of CaC, and residual glomerular filtration rate;
Table 2) were not significantly associated. Daily dose of
CaC was not significantly associated with the variability of
change in serum inorganic phosphorus during the interdia-
lysis interval.
Effect of different ARs on serum inorganic phosphorus
levels
In the AR + CaC group, 73 and 12 patients were pre-
scribed one of the PPIs (8 esomeprazole [20 mg/day], 33
lansoprazole [18 ± 6 mg/day], 20 omeprazole [20 ± 2 mg/
day], and 12 rabeprazole [11 ± 3 mg/day]) and one of
the H2RAs (10 famotidine [12 ± 4 mg/day], 2 ranitidine
[150 mg/day]), respectively. No significant heterogen-
eity was observed regarding hemodialysis intervals
(48 h vs 72 h) across different ARs (p = 0.101). Multiple
comparisons showed no significant difference in the in-
crease in serum inorganic phosphorus level during the
interdialysis interval among the ARs examined, excluding
ranitidine. Because only 2 patients were given ranitidine,
these patients were excluded from comparison (Fig. 4).
Corrected serum calcium levels
Figure 5 shows changes in corrected serum calcium level
in post-HD and pre-HD measurements in the CaC and
AR + CaC groups. The AR + CaC group showed signifi-
cantly greater decrease in corrected serum calcium level
compared to the CaC group (p = 0.026).
Fracture events
Fracture events were searched by reviewing medical re-
cords throughout the study period for the patients ana-
lyzed. There was no significant difference in incidence of
fracture events between the CaC and AR + CaC groups:
5 events out of 23 (22%) and 19 events out of 85 (22%)
patients in the CaC and AR + CaC groups, respectively.
Discussion
In the present study we revealed that concomitant ad-
ministration of ARs with CaC significantly attenuated
the hypophosphatemic effects of CaC in Japanese pa-
tients, particularly in those undergoing hemodialysis
with a 72-h interdialysis interval. Our finding is consist-
ent with that of Matsunaga et al. [10] from an observa-
tional study in 115 hemodialysis patients. They reported
Fig. 1 Flow chart of patient selection. CaC, calcium carbonate; AR, acid reducer
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that the average pre-hemodialysis serum inorganic phos-
phorus level measured over 2 months after the initiation
of concomitant treatment with CaC and famotidine
(10 mg/day) or lansoprazole (30 mg/day) was significantly
higher than the respective baseline value obtained with
CaC alone [famotidine: 5.79 ± 1.17 vs. 5.55 ± 1.21 mg/dL
(p < 0.05); lansoprazole: 5.80 ± 0.98 vs. 5.36 ± 1.39 mg/dL
(p < 0.05)]. In contrast, Hardy et al. [15] conducted a
prospective crossover trial in 16 hemodialysis patients
treated with CaC alone for the initial 2 months and then
switched to concomitant CaC and omeprazole (20 mg/
day) for 2 months. They found no significant difference
in mean serum inorganic phosphorus level between
CaC alone (1.80 ± 0.38 mM) and CaC with omeprazole
(1.89 ± 0.42 mM). At present, we cannot explain the
discrepancies in findings described above. However, we
assume that many clinical covariates are associated with
inter-patient variability of serum inorganic phosphorus con-
centrations and their relative contribution to overall vari-
ability would be different among patients. In this context,
our study design that compares the magnitude of increase
in serum inorganic phosphorus levels during the interdialy-
sis period in the same patients have allowed more sensitive
detection of the interaction between ARs and CaC.
In the present study we observed a significant drug
interaction between ARs and CaC only in patients who
Table 1 Demographic and laboratory data of patients studied
Characteristics CaC group AR + CaC group P value
Number of patients, n 23 85 -
Male, n (%) 14 (61) 55 (65) 0.734
Age, years 66 ± 12 70 ± 12 0.172
Total body weight, kg 56.3 ± 9.3 53.8 ± 12.1 0.362
Dry weight, kg 54.9 ± 9.1 52.3 ± 12.0 0.347
Dialysis time, min 199 ± 27 212 ± 28 0.060
Dose of calcium carbonate, g/day 1.9 ± 1.1 2.5 ± 1.3 0.062
Pre-HD blood urea nitrogen, mg/dL 53.0 ± 13.2 54.2 ± 17.9 [n = 83] 0.771
Pre-HD serum creatinine, mg/dL 7.53 ± 2.24 8.26 ± 2.77 0.246
Pre-HD estimated GFR, mL/min/1.73 m2 6.2 ± 2.0 5.9 ± 2.6 0.561
Serum albumin, g/dL 3.0 ± 0.6 [n = 20] 3.3 ± 0.6 [n = 80] 0.152
Alkaline phosphatase, IU/L 437 ± 336 [n = 10] 304 ± 188 [n = 20] 0.266
Intact parathyroid hormone, pg/mL 25 [n = 1] 93.8 ± 84.7 [n = 14] -
Post-HD serum inorganic phosphorus, mg/dL 2.3 ± 0.7 2.1 ± 0.7 0.329
Post-HD serum calcium, mg/dL 8.8 ± 0.9 [n = 22] 9.0 ± 0.6 [n = 84] 0.238
Post-HD corrected serum calcium, mg/dL 9.6 ± 1.0 [n = 19] 9.6 ± 0.6 [n = 84] 0.984
Co-morbidities
Hypertension, n (%) 17 (74) 62 (73) 0.926
Dyslipidemia, n (%) 2 (9) 16 (19) 0.279
Type 2 diabetes, n (%) 14 (61) 40 (47) 0.240
Heart disease, n (%) 8 (35) 40 (47) 0.293
Peptic ulcer disease, n (%) 0 (0) 6 (7) -
Mineral and bone disorder, n (%) 4 (17) 11 (13) 0.626
Parathyroid disorder, n (%) 5 (22) 8 (9) 0.105
Gastric acid reducers
Proton pump inhibitors, n (%) - 73 (86) -
Histamine H2 receptor antagonists, n (%) - 12 (14) -
Osteoactive drugs
Vitamin D3 analogues, n (%) 5 (22) 24 (28) 0.533
Bisphosphonates, n (%) 0 (0) 0 (0) -
Calcium sensitizers, n (%) 0 (0) 0 (0) -
Data are expressed as mean ± standard deviation, or number (percentage)
AR acid reducer, CaC calcium carbonate, GFR glomerular filtration rate, HD hemodialysis
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underwent hemodialysis with a 72-h interval (Fig. 3b).
While a similar trend was observed in patients with a
48-h interdialysis interval, the difference did not reach a
significant level (p = 0.118, Fig. 3a). This finding may be
explained by the smaller sample size for the 48-h interval
(n = 36) compared to the 72-h interval (n = 72). Indeed,
the differences in mean increase of serum inorganic phos-
phorus level (pre-HD vs. post-HD) were comparable for
the 48- and 72-h interdialysis intervals (1.9 vs. 1.3 mg/dL
and 2.3 vs. 1.6 mg/dL, respectively). In addition, our multi-
variate analysis detected interdialysis interval of 72 h as a
statistically significant covariate for the magnitude of in-
crease in serum inorganic phosphorus concentration dur-
ing the interdialysis interval after adjusting concomitant
use of AR, sex, age, dry weight, daily dose of CaC, and re-
sidual GFR (Table 2). These data appear to support an idea
that interdialysis interval would be an important factor for
the interaction between AR and CaC. Nevertheless, be-
cause the present study is a retrospective in design, it is
difficult to rule out the multicollineality by only evaluating
heterogeneity and internal correlation in the selective vari-
ables. Therefore, we cannot draw a conclusive statement
regarding the positive correlation between interdialysis
interval and hypophosphatemic effects in patients receiv-
ing AR and CaC.
There is a large inter-patient variability in serum inorganic
phosphorus concentration irrespective of hemodialysis
interval and co-administration of ARs, because serum
inorganic phosphorus concentration is controlled not
only by the extent of intestinal absorption of dietary
phosphate but also by parathyroid hormone level, acid-
osis that causes phosphorus shift from the intracellular
to serum compartment, and other factors. In this context,
it may be important to employ a study design that allows
pair-wise comparisons of data in the same patients. If we
had compared the pre-HD and post-PD serum inorganic
phosphorus concentrations obtained from different
patients, we might have failed to detect a significant
difference.
The attenuation of hypophosphatemic effects of CaC
by ARs is most likely due to reduced phosphate binding
capacity of CaC by ARs in the upper gastrointestinal
tract. Precipitated CaC formulations are known to show
Fig. 2 Changes in serum inorganic phosphorus levels of paired
samples collected after dialysis and just before dialysis session.
CaC, calcium carbonate; AR, acid reducer; HD, hemodialysis
a b
Fig. 3 Changes in serum inorganic phosphorus levels of paired samples collected after dialysis and just before dialysis session in patients
undergoing hemodialysis with 48-h interdialysis interval (a) and 72-h interdialysis interval (b). Bonferroni’s corrections were applied for the
p-values. CaC, calcium carbonate; AR, acid reducer; HD, hemodialysis
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pH-dependent dissolution rates [12]. Co-administration
of ARs with CaC would slow the dissolution of CaC
formulation, consequently releasing smaller amount of
calcium ions to bind phosphate, compared to when CaC is
administered alone. In this context, we examined whether
there is any difference among ARs in terms of the extent
of interaction with CaC, because Hirschowitz et al. [18]
reported that PPIs inhibited gastric acid secretion to a
greater extent than H2RAs. In our study, 63 patients re-
ceived a PPI and 10 received an H2RA. Multiple com-
parisons suggested that the magnitude of increase in
serum inorganic phosphorus level during the interdialy-
sis duration was comparable between different PPIs
(Fig. 4). We were not able to draw any conclusion re-
garding the difference in AR-CaC interaction between
PPIs and H2RAs, because the number of patients re-
ceiving H2RAs was much smaller than those receiving
PPIs. As a logical extrapolation based upon the results
of the present study, a concomitant use of antacids
containing either aluminum or magnesium hydroxide
and the combination thereof (e.g., Maalox®) with CaC
may also affect the hypophosphatemic effects of CaC.
However, no patients receiving antacids with CaC were
retrieved from our electronic medical records. The most
plausible reason for this finding would be that aluminum
containing antacids are contraindicated for hemodialysis
patients.
If co-administration of ARs with CaC attenuates the
hypophosphatemic effects of CaC, it may also affect serum
calcium homeostasis. Hyperphosphatemia is known to
trigger hyperparathyroidism via the physicochemical in-
verse equilibrium between serum phosphorus and calcium
concentrations [19] and subsequently increase the risk
of hip fracture by 4 to 5 times in chronic hemodialysis
patients compared to the general population [20]. Al-
though we found a significant difference in the change
Table 2 Results of multiple regression analysis investigating the association of various clinical covariates with interpatient variability
in the magnitude of increase in serum inorganic phosphorus concentration during the interdialysis interval in Japanese hemodialysis
patients (n = 108)
Covariate PRC SE SPRC VIF P
Intercept 1.56 0.95 0.0 - 0.103
Concomitant use of AR 0.374 0.119 0.313 1.21 0.002
Female 0.116 0.112 0.114 1.49 0.306
Age (years) −0.00802 0.00815 −0.102 1.31 0.327
Dry weight (kg) 0.0124 0.0108 0.145 1.93 0.252
Daily dose of CaC (g/day) 0.0357 0.0746 −0.0473 1.19 0.633
Interdialysis interval of 72 h 0.206 0.100 0.198 1.14 0.043
Residual GFR (mL/min/1.73 m2) 0.0060 0.0410 0.0167 1.60 0.885
AR acid reducers, CaC calcium carbonates, GFR glomerular filtration rate, PRC partial regression coefficient, SE standard error of PRC, SPRC standardized partial
regression coefficient, VIF variance inflation factors
Fig. 4 Effects of different ARs on change in serum inorganic
phosphorus concentration. Error bar indicates standard deviation.
AR, acid reducer
Fig. 5 Changes in albumin-corrected serum calcium levels of paired
samples collected after dialysis and just before dialysis session.
CaC, calcium carbonate; AR, acid reducer; HD, hemodialysis
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in albumin-corrected serum calcium concentration be-
tween patients receiving CaC alone and those receiving
CaC with ARs (Fig. 4), the difference (0.3 mg/dL) was
small and clinically irrelevant. In addition, we found no
significant difference in incidence of fracture events
after initiating chronic hemodialysis between patients
treated with CaC alone and those with CaC and AR [5/
23 (22%) and 19/85 (22%), respectively]. Further studies
with larger numbers of patients are required to conclude
the effects of AR on bone complications in hemodialysis
patients. Indeed, there are reports indicating that PPIs
per se potentially increase fracture risk in the general
population [21, 22].
The present study has several limitations that are in-
herent to the study design. Firstly, no information was
available regarding the patients’ adherence to medications
and dietary consumption of phosphorus and calcium dur-
ing the study period. Secondly, plasma concentrations of
parathyroid hormone were measured in only less than
15% of patients. Thirdly, it remains unclear whether our
data obtained from hemodialysis patients receiving CaC
may be extrapolated to those receiving another type of
calcium salt phosphate binder, calcium acetate. While
calcium acetate is approved in the United States and
Europe, it is not approved as an ethical drug in Japan.
Fourthly, because the observation period of our study
was short (median [interquartile range]: 38 [17, 68]
days), it remains to be determined if our findings can
be extrapolated to an extended observation period. Fi-
nally, we were not able to investigate whether a con-
comitant administration of PPI or H2RA with other
phosphate binders (i.e., sevelamer hydrochloride, lan-
thanum carbonate, bixalomer, and ferric citrate) would
affect their hypophosphatemic effects. This was simply
due to a scarcity of data: only 13 relevant patients were
identified in the electronic medical records.
Conclusion
Concomitant use of ARs, especially PPIs, with CaC may
attenuate the hypophosphatemic effect of CaC in patients
undergoing chronic hemodialysis. When patients are taking
ARs for the prevention of upper gastrointestinal damages
(such as peptic ulcer) due to long-term use of low-dose
aspirin or other antiplatelet drugs, it may be prudent to
choose phosphorus binders other than CaC.
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